• Company
• Jemperli expands indication to all endometrial cancers
• by Whang, byung-woo Dec 11, 2024 05:52am

• Company
• MM drug Revlimid continues to thrive after patent expiry
• by Eo, Yun-Ho Dec 11, 2024 05:52am

• Company
• Antibiotic clarithromycin market grows fourfold in 3 yrs
• by Chon, Seung-Hyun Dec 10, 2024 05:53am

• Company
• 1st MET-targeting anticancer drug likely to get reimb in KOR
• by Eo, Yun-Ho Dec 10, 2024 05:53am

• Company
• GC Biopharma&Dong-A ST research mRNA-LNP-based treatment
• by Kim, Jin-Gu Dec 10, 2024 05:52am

• Company
• ‘Pluvicto, a new standard therapy for prostate cancer?'
• by Whang, byung-woo Dec 10, 2024 05:52am

• Company
• Padcev seeks reimb as mono and combo therapy in KOR
• by Eo, Yun-Ho Dec 9, 2024 05:47am

• Company
• New treatment options for pancreatic cancer arise
• by Son, Hyung Min Dec 9, 2024 05:47am

• Company
• Auto part company confirms potential of novel antibody drug
• by Son, Hyung Min Dec 9, 2024 05:46am

• Company
• ‘Various treatment options emerged for ulcerative colitis'
• by Son, Hyung Min Dec 6, 2024 05:57am